Atorvastatin Therapy Improves Triglyceride/HDL-Cholesterol Ratio and Lipid Profile in Dyslipidemic Patients
Keywords:
Triglyceride to high-density lipoprotein cholesterol ratio, Statin, Dyslipidemia, Cardiovascular disease, Lipid parametersAbstract
Dyslipidemia is a known risk factor for atherosclerosis and cardiovascular diseases, and statins are commonly used to mitigate this risk. Evidence has indicated that the triglyceride/HDL-cholesterol ratio (TG/HDL-C ratio) can be used to estimate small dense LDL (sdLDL), a lipoprotein that may contribute to atherosclerosis and cardiovascular diseases. This study aimed to assess the efficacy of atorvastatin in 104 dyslipidemic patients aged 28 to 80 years at Nakhon Pathom Hospital by collecting retrospective data and comparing the TG/HDL-C ratio and other lipid parameters before and after treatment with atorvastatin (40 mg) over 3 and 6 months. The results showed a significant decrease in the TG/HDL-C ratio after both 3 and 6 months of treatment compared to pre-treatment levels (p < 0.05). Additionally, other lipid parameters, including total cholesterol, triglyceride, LDL-cholesterol, and non-HDL-cholesterol, showed significant reduction after treatment (p < 0.05). Furthermore, the TG/HDL-C ratio was positively correlated with triglyceride (r = 0.920) and non-HDL-cholesterol (r = 0.253) (p < 0.05) and negatively correlated with HDL-cholesterol (r = -0.485) (p < 0.05). In conclusion, atorvastatin (40 mg) effectively reduced the TG/HDL-C ratio from 3 months onwards, indicating a decrease in sdLDL-cholesterol and a reduced risk of cardiovascular diseases in dyslipidemic patients.
References
Bureau of Non-Communicable Diseases, Department of Disease Control, Ministry of Public Health. Annual Report 2022. Bangkok; 2565. (in Thai)
Martone AM, Landi F, Petricca L, et al. Prevalence of dyslipidemia and hypercholesterolemia awareness: results from the Lookup 7+ online project. Eur J Public Health 2022; 32: 402–7.
National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143–421.
Mingpakanee R. The role of small dense LDL in the pathogenesis of coronary artery disease. J Med Tech Assoc Thailand 2018; 46: 6657–70.
Emadzadeh MR, Alavi MS, Soukhtanloo M, et al. Changes in small dense low-density lipoprotein levels following acute coronary syndrome. Angiology 2013; 64: 216–22.
Sakai K, Koba S, Nakamura Y, et al. Small dense low-density lipoprotein cholesterol is a promising biomarker for secondary prevention in older men with stable coronary artery disease. Geriatr Gerontol Int 2018; 18: 965–72.
Bahadir MA, Oguz A, Uzunlulu M, Bahadir O. Effects of different statin treatments on small dense low-density lipoprotein in patients with metabolic syndrome. J Atheroscler Thromb 2009; 16: 684–90.
Nozue T, Michishita I, Ito Y, Hirano T. Effects of statin on small dense low-density lipoprotein cholesterol and remnant-like particle cholesterol in heterozygous familial hypercholesterolemia. J Atheroscler Thromb 2008; 15: 146–53.
Jacob RF, Walter MF, Self-Medlin Y, Mason RP. Atorvastatin active metabolite inhibits oxidative modification of small dense low-density lipoprotein. J Cardiovasc Pharmacol 2013; 62: 160–6.
Yoshino G. Rosuvastatin reduces plasma small dense LDL-cholesterol predominantly in non-diabetic hypercholesterolemic patients. Pharmacology & Pharmacy 2012; 3: 72–8.
Kosmas CE, Rodriguez Polanco S, Bousvarou MD, et al. The triglyceride/high-density lipoprotein cholesterol (TG/HDL-C) ratio as a risk marker for metabolic syndrome and cardiovascular disease. Diagnostics (Basel) 2023; 13.
Salazar MR, Carbajal HA, Espeche WG, et al. Use of the plasma triglyceride/high-density lipoprotein cholesterol ratio to identify cardiovascular disease in hypertensive subjects. J Am Soc Hypertens 2014; 8: 724–31.
Tani S, Imatake K, Suzuki Y, et al. Triglyceride/high-density lipoprotein cholesterol ratio may be a better index of cardiometabolic risk in women than in men in Japan. Nutr Metab Cardiovasc Dis 2024; 34: 868–81.
Tani S. The ratio of triglyceride to high-density lipoprotein cholesterol as an indicator of risk stratification for atherosclerotic cardiovascular disease in a clinical setting. Intern Med 2020; 59: 2639–40.
Maruyama C, Imamura K, Teramoto T. Assessment of LDL particle size by triglyceride/HDL-cholesterol ratio in non-diabetic, healthy subjects without prominent hyperlipidemia. J Atheroscler Thromb 2003; 10: 186–91.
Yokoyama K, Tani S, Matsuo R, Matsumoto N. Increased triglyceride/high-density lipoprotein cholesterol ratio may be associated with reduction in the low-density lipoprotein particle size: assessment of atherosclerotic cardiovascular disease risk. Heart Vessels 2019; 34: 227–36.
St-Pierre AC, Cantin B, Dagenais GR, et al. The triglyceride/high-density lipoprotein cholesterol ratio, the small dense low-density lipoprotein phenotype, and ischemic heart disease risk. Metab Syndr Relat Disord 2004; 2: 57–64.
Lertthiraphan S. Lipid-lowering drugs for the prevention of coronary artery disease. J Med Health Sci 2020; 27: 147–59.
Committee TNDSD. National essential medicines list and evidence-based medicine, August 2022. Available from: https://ndi.fda.moph.go.th/drug_national/search
Deerochanawong C, Buranakitjaroen P, Nitiyanant W, et al. The atorvastatin Goal achievement across risk levels: (ATGOAL) study in Thailand. J Med Assoc Thai 2007; 90: 72–81.
Miki T, Suruga K, Ichikawa K, et al. Triglyceride to HDL-cholesterol ratio is a predictor of future coronary events: a possible role of high-risk coronary plaques detected by coronary CT angiography. Eur Heart J 2020; 41: ehaa946-2930.
Sahebkar M, Khalilzadeh N, Movahedzadeh J, et al. Comparison of the effect of 40 and 80 mg/day doses of atorvastatin on changes in lipid profiles among acute coronary syndrome patients: a randomized clinical trial study. J Res Med Sci 2023; 28: 24.
Adams SP, Tsang M, Wright JM. Lipid-lowering efficacy of atorvastatin. Cochrane Database Syst Rev 2015; CD008226.
Meor Anuar Shuhaili MFR, Samsudin IN, Stanslas J, et al. Effects of different types of statins on lipid profile: a perspective on Asians. Int J Endocrinol Metab 2017; 15: e43319.
Srisawasdi P, Chaloeysup S, Teerajetgul Y, et al. Estimation of plasma small dense LDL cholesterol from classic lipid measures. Am J Clin Pathol 2011; 136: 20–9.
Moriyama K. The association between the triglyceride to high-density lipoprotein cholesterol ratio and low-density lipoprotein subclasses. Intern Med 2020; 59: 2661–9.
Quispe R, Manalac RJ, Faridi KF, et al. Relationship of the triglyceride to high-density lipoprotein cholesterol (TG/HDL-C) ratio to the remainder of the lipid profile: the very large database of Lipids-4 (VLDL-4) study. Atherosclerosis 2015; 242: 243–50.
Kathiresan S, Otvos JD, Sullivan LM, et al. Increased small low-density lipoprotein particle number: a prominent feature of the metabolic syndrome in the Framingham Heart Study. Circulation 2006; 113: 20–9.
Sposito AC, Chapman MJ. Statin therapy in acute coronary syndromes: mechanistic insight into clinical benefit. Arterioscler Thromb Vasc Biol 2002; 22: 1524–34.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Journal of the Medical Technologist Association of Thailand
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
